ALDH1A1‐related stemness in high‐grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR‐PI3K/aurora kinase inhibitors

OUP accepted manuscript

(2018)   ANNALS OF ONCOLOGY

High ALDH activity defines ovarian cancer stem-like cells with enhanced invasiveness and EMT progress which are responsible for tumor invasion

(2018) Yiying Li et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Dual Src and MEK inhibition decreases ovarian cancer growth and targets tumor initiating stem-like cells

(2018) Fiona Simpkins et al.   CLINICAL CANCER RESEARCH

The prognostic impact of cancer stem-like cell biomarker aldehyde dehydrogenase-1 (ALDH1) in ovarian cancer: A meta-analysis

(2018) Ilary Ruscito et al.   GYNECOLOGIC ONCOLOGY

A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors

(2018) Michael Carducci et al.   INVESTIGATIONAL NEW DRUGS

Synthetic Lethality Interaction Between Aurora Kinases and CHEK1 Inhibitors in Ovarian Cancer

(2017) Ana Alcaraz-Sanabria et al.   MOLECULAR CANCER THERAPEUTICS

A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer

(2017) Zev A. Wainberg et al.   Targeted Oncology

Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells

(2017) Majid Momeny et al.   Scientific Reports

An active IGF-1R-AKT signaling imparts functional heterogeneity in ovarian CSC population

(2016) Ram K. Singh et al.   Scientific Reports

SePIA: RNA and small RNA sequence processing, integration, and analysis

(2016) Katherine Icay et al.   BioData Mining

Identification of Prognostic Groups in High-Grade Serous Ovarian Cancer Treated with Platinum-Taxane Chemotherapy

(2015) P. Chen et al.   CANCER RESEARCH

Formation of stable small cell number three-dimensional ovarian cancer spheroids using hanging drop arrays for preclinical drug sensitivity assays

(2015) Shreya Raghavan et al.   GYNECOLOGIC ONCOLOGY

Ovary and fimbrial stem cells: biology, niche and cancer origins

(2015) Annie Ng et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies

(2014) Bhagwan Yadav et al.   Scientific Reports

Immunohistochemical expression and prognostic relevance of Bmi-1, a stem cell factor, in epithelial ovarian cancer

(2013) Amal Abd El hafez et al.   Annals of Diagnostic Pathology

BMI-1 activation is crucial in hTERT-induced epithelial–mesenchymal transition of oral epithelial cells

(2013) Bin Qiao et al.   EXPERIMENTAL AND MOLECULAR PATHOLOGY

A three-dimensional microenvironment alters protein expression and chemosensitivity of epithelial ovarian cancer cells in vitro

(2013) Janet Myungjin Lee et al.   LABORATORY INVESTIGATION

IGF-1R and Bmi-1 expressions in lung adenocarcinoma and their clinicopathologic and prognostic significance

(2013) Xueyan Zhang et al.   TUMOR BIOLOGY

Evaluating cell lines as tumour models by comparison of genomic profiles

(2013) Silvia Domcke et al.   Nature Communications

Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia

(2013) T. Pemovska et al.   Cancer Discovery

Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation

(2012) Maria Vinci et al.   BMC BIOLOGY

CIP2A overexpression is associated with c-Myc expression in colorectal cancer

(2012) Camilla Böckelman et al.   CANCER BIOLOGY & THERAPY

Ovarian cancer stem cells: Working towards the root of stemness

(2012) Rosemary Foster et al.   CANCER LETTERS

Lin28 regulates BMP4 and functions with Oct4 to affect ovarian tumor microenvironment

(2012) Wei Ma et al.   CELL CYCLE

Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma

(2012) Ursula A. Matulonis et al.   GYNECOLOGIC ONCOLOGY

Prognostic Impact of the Cancer Stem Cell–Related Marker NANOG in Ovarian Serous Carcinoma

(2012) Maria Lee et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

The evolving concept of cancer and metastasis stem cells

(2012) Irène Baccelli et al.   JOURNAL OF CELL BIOLOGY

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

Aldehyde Dehydrogenase in Combination with CD133 Defines Angiogenic Ovarian Cancer Stem Cells That Portend Poor Patient Survival

(2011) I. A. Silva et al.   CANCER RESEARCH

Inhibition of Aurora-A kinase induces cell cycle arrest in epithelial ovarian cancer stem cells by affecting NFĸB pathway

(2011) Ilana Chefetz et al.   CELL CYCLE

Aldehyde dehydrogenase: Its role as a cancer stem cell marker comes down to the specific isoform

(2011) Paola Marcato et al.   CELL CYCLE

Stem Cell Pathways Contribute to Clinical Chemoresistance in Ovarian Cancer

(2011) A. D. Steg et al.   CLINICAL CANCER RESEARCH

Integrated genomic analyses of ovarian carcinoma

(2011) D. Bell et al.   NATURE

The cancer stem cell: premises, promises and challenges

(2011) Hans Clevers   NATURE MEDICINE

A more efficient method to generate integration-free human iPS cells

(2011) Keisuke Okita et al.   NATURE METHODS

Targeting Aldehyde Dehydrogenase Cancer Stem Cells in Ovarian Cancer

(2010) C. N. Landen et al.   MOLECULAR CANCER THERAPEUTICS

Distinct Expression Levels and Patterns of Stem Cell Marker, Aldehyde Dehydrogenase Isoform 1 (ALDH1), in Human Epithelial Cancers

(2010) Shan Deng et al.   PLoS One

ALDH1 expression correlates with favorable prognosis in ovarian cancers

(2009) Bin Chang et al.   MODERN PATHOLOGY

Spheroid-based drug screen: considerations and practical approach

(2009) Juergen Friedrich et al.   Nature Protocols

Survival-Related Profile, Pathways, and Transcription Factors in Ovarian Cancer

(2009) Anne P. G Crijns et al.   PLOS MEDICINE